Research programme: cyclin dependent kinase inhibitors - Quest PharmaTech

Drug Profile

Research programme: cyclin dependent kinase inhibitors - Quest PharmaTech

Alternative Names: 2127 (CDK immunomodulator) - Quest PharmaTech; ACP-2127

Latest Information Update: 30 Jul 2013

Price : $50

At a glance

  • Originator Quest PharmaTech
  • Class Antineoplastics; Macrolides
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 30 Jul 2013 Discontinued - Preclinical for Cancer in Canada (unspecified route) before 2013
  • 07 Dec 2006 Suspended - Preclinical for Cancer in Canada (unspecified route)
  • 14 Oct 2005 Altachem Pharma is now called Quest PharmaTech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top